-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, HnuoCZ5ku/qS2s3fba+0Ns4QtmZFCWqBoWbssbdIdwAO4i+vwGtbS4rUxAOZukdY JOpKdz6U4ps/Kb/2a7u2vg== 0000897101-04-000452.txt : 20040308 0000897101-04-000452.hdr.sgml : 20040308 20040308162537 ACCESSION NUMBER: 0000897101-04-000452 CONFORMED SUBMISSION TYPE: 15-12G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20040308 EFFECTIVENESS DATE: 20040308 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CELOX LABORATORIES INC CENTRAL INDEX KEY: 0000883720 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 363384240 STATE OF INCORPORATION: MN FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 15-12G SEC ACT: 1934 Act SEC FILE NUMBER: 000-19866 FILM NUMBER: 04655045 BUSINESS ADDRESS: STREET 1: 1311 HELMO AVE CITY: ST PAUL STATE: MN ZIP: 55128 BUSINESS PHONE: 6517301500 MAIL ADDRESS: STREET 1: 1311 HELMO AVE CITY: ST PAUL STATE: MN ZIP: 55128 FORMER COMPANY: FORMER CONFORMED NAME: CELOX CORPORATION DATE OF NAME CHANGE: 19930328 15-12G 1 protide041244_15.htm Protide Pharmaceuticals, Inc. Form 15-12G

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g)
OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File No. 0-19866

Protide Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)

1311 Helmo Avenue
Saint Paul, Minnesota 55128
(651) 730-1500

(Address, including zip code, and telephone number, including
area code, of registrant’s principal executive offices)

Common Stock, par value $0.01 per share
(Title of each class of securities covered by this Form)

NONE
(Titles of all other classes of securities for which
a duty to file reports under Section 13(a) or 15(d) remains)

        Place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)(i)   [X]   Rule 12h-3(b)(1)(i)   [   ]  
Rule 12g-4(a)(1)(ii)  [   ]  Rule 12h-3(b)(1)(ii)  [   ] 
Rule 12g-4(a)(2)(i)  [   ]  Rule 12h-3(b)(2)(i)  [   ] 
Rule 12g-4(a)(2)(ii)  [   ]  Rule 12h-3(b)(2)(ii)  [   ] 
      Rule 15d-6  [   ] 

        Approximate number of holders of record as of the certification or notice date:   185

        Pursuant to the requirements of the Securities Exchange Act of 1934, Protide Pharmaceuticals, Inc. has caused this Certification/Notice to be signed on its behalf by the undersigned duly authorized person.

           
    PROTIDE PHARMACEUTICALS, INC.


Dated:   March 8, 2004


By:  
 

/s/   Milo R. Polovina
 
 
  Name:   Milo R. Polovina 
  Title:   Chief Executive Officer 






-----END PRIVACY-ENHANCED MESSAGE-----